Merck & Co., Inc. $MRK Shares Purchased by Diversify Advisory Services LLC

Key Points

• Institutional ownership increased: Diversify Advisory Services raised its Merck position by 32.5% to 38,612 shares worth $5.6 million. Institutional investors collectively own 76.07% of the company.
• Shares and dividend: Merck stock opened at $149.98, near its 52-week high, while the company maintains a quarterly dividend of $0.85 per share, or a 2.3% annual yield.
• Positive catalysts face longer-term risks: Analysts generally remain favorable, with a consensus “Moderate Buy” rating and a $151.92 price target, and the European approval of KEYTRUDA plus Padcev offers growth potential. However, slowing KEYTRUDA growth, the patent cliff and insider selling remain concerns.

Diversify Advisory Services LLC increased its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 32.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,612 shares of the company's stock after purchasing an additional 9,477 shares during the period. Diversify Advisory Services LLC's holdings in Merck & Co., Inc. were worth $5,606,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. BlackRock Inc. increased its stake in Merck & Co., Inc. by 0.5% during the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company's stock valued at $29,169,479,000 after purchasing an additional 1,073,507 shares in the last quarter. State Street Corp raised its holdings in Merck & Co., Inc. by 0.9% in the second quarter. State Street Corp now owns 120,413,256 shares of the company's stock worth $15,573,754,000 after buying an additional 1,087,583 shares during the last quarter. Wellington Management Group LLP raised its holdings in Merck & Co., Inc. by 2.3% in the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company's stock worth $11,083,033,000 after buying an additional 1,934,312 shares during the last quarter. Bank of America Corp DE raised its holdings in Merck & Co., Inc. by 10.5% in the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company's stock worth $3,701,831,000 after buying an additional 2,919,780 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Merck & Co., Inc. by 23.8% in the first quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company's stock worth $1,858,938,000 after buying an additional 2,969,856 shares in the last quarter. Institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Trading Up 1.1%

Merck & Co., Inc. stock opened at $149.98 on Thursday. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. Merck & Co., Inc. has a one year low of $82.01 and a one year high of $156.92. The stock has a market capitalization of $370.02 billion, a PE ratio of 119.98, a price-to-earnings-growth ratio of 6.85 and a beta of 0.21. The business's fifty day moving average is $146.55 and its 200 day moving average is $129.88.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The company had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same period last year, the company earned $2.13 EPS. Merck & Co., Inc.'s revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, sell-side analysts predict that Merck & Co., Inc. will post 2.66 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio (DPR) is presently 272.00%.

Insider Transactions at Merck & Co., Inc.

In related news, EVP Chirfi Guindo sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the transaction, the executive vice president owned 36,613 shares in the company, valued at $4,942,755. This represents a 21.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Richard R. Deluca sold 11,699 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the transaction, the executive vice president owned 110,167 shares in the company, valued at approximately $14,501,282.21. This trade represents a 9.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 228,238 shares of company stock valued at $29,977,783. Company insiders own 0.17% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on MRK. Guggenheim increased their price target on shares of Merck & Co., Inc. from $146.00 to $170.00 and gave the company a "buy" rating in a report on Tuesday, September 8th. TD Cowen raised their price target on shares of Merck & Co., Inc. from $137.00 to $155.00 and gave the company a "hold" rating in a research report on Wednesday, September 23rd. Cantor Fitzgerald boosted their price objective on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the stock a "neutral" rating in a report on Thursday, October 8th. Wall Street Zen lowered shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating in a report on Saturday, October 3rd. Finally, CICC Research initiated coverage on Merck & Co., Inc. in a research report on Wednesday, June 24th. They issued an "outperform" rating and a $138.00 price objective on the stock. Seventeen research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $151.92.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The European Commission approved KEYTRUDA plus Padcev as perioperative treatment for adults with resectable muscle-invasive bladder cancer. The expanded indication strengthens Merck’s oncology portfolio, supports additional long-term revenue opportunities and reinforces the commercial value of the two-drug combination. European Commission KEYTRUDA and Padcev approval
• Positive Sentiment: The latest trading session saw Merck outperform the broader market, reflecting investor interest in its strong oncology franchise and recent product catalysts. Merck outperforms the stock market
• Neutral Sentiment: Merck’s participation in the growing bioconjugation and cell-culture-media markets provides potential exposure to expanding biopharmaceutical research demand, but the reports offer no specific financial impact or new company guidance. Bioconjugation market report Cell culture media market report
• Neutral Sentiment: Reports on Merck’s phase 3 melanoma results and ETF selling could influence sentiment, but the available information does not provide enough detail to assess the magnitude or durability of either development. Merck phase 3 melanoma results
• Negative Sentiment: Zacks Research downgraded Merck from “hold” to “strong sell,” adding selling pressure and highlighting valuation or growth concerns.
• Negative Sentiment: KEYTRUDA and KEYTRUDA QLEX remain Merck’s primary earnings engine, while U.S. growth is expected to moderate as the drug approaches peak penetration. The looming patent cliff and a legal setback affecting subcutaneous KEYTRUDA sales in several European markets increase concerns about Merck’s ability to replace future lost revenue with newer treatments. Merck KEYTRUDA growth and patent cliff analysis

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck's principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.